GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » EPS without NRI

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) EPS without NRI : $-1.40 (TTM As of Mar. 2016)


View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals EPS without NRI?

Cancer Prevention Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2016 was $-0.60. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2016 was $-1.40.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cancer Prevention Pharmaceuticals's EPS without NRI or its related term are showing as below:

CPP's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 10.6
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Cancer Prevention Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2016 was $-0.44. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 was $-0.97.

Cancer Prevention Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2016 was $-0.44. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2016 was $-0.97.


Cancer Prevention Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals EPS without NRI Chart

Cancer Prevention Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15
EPS without NRI
- - -1.64

Cancer Prevention Pharmaceuticals Quarterly Data
Dec13 Dec14 Mar15 Sep15 Dec15 Mar16
EPS without NRI Get a 7-Day Free Trial - - - -0.80 -0.60

Competitive Comparison of Cancer Prevention Pharmaceuticals's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cancer Prevention Pharmaceuticals's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's PE Ratio without NRI falls into.



Cancer Prevention Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cancer Prevention Pharmaceuticals  (AMEX:CPP) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cancer Prevention Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Headlines